A Randomised, Double Blind (Sponsor Unblinded), Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs GSK 2831781 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 24 Jul 2017 Planned End Date changed from 3 Jun 2018 to 15 Aug 2018.
- 24 Jul 2017 Planned primary completion date changed from 3 Jun 2018 to 15 Aug 2018.
- 10 Jun 2017 Biomarkers information updated